- Home
- TLRY vs KNSA Comparison
TLRY vs KNSA Comparison
Compare TLRY & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLRY
- KNSA
- Stock Information
- Founded
- TLRY N/A
- KNSA 2015
- Country
- TLRY Canada
- KNSA United Kingdom
- Employees
- TLRY N/A
- KNSA N/A
- Industry
- TLRY Medicinal Chemicals and Botanical Products
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- TLRY Health Care
- KNSA Health Care
- Exchange
- TLRY Nasdaq
- KNSA Nasdaq
- Market Cap
- TLRY 1.5B
- KNSA 1.7B
- IPO Year
- TLRY 2018
- KNSA 2018
- Fundamental
- Price
- TLRY $1.35
- KNSA $21.29
- Analyst Decision
- TLRY Hold
- KNSA Strong Buy
- Analyst Count
- TLRY 3
- KNSA 5
- Target Price
- TLRY $1.88
- KNSA $36.60
- AVG Volume (30 Days)
- TLRY 30.1M
- KNSA 355.3K
- Earning Date
- TLRY 01-07-2025
- KNSA 10-29-2024
- Dividend Yield
- TLRY N/A
- KNSA N/A
- EPS Growth
- TLRY N/A
- KNSA N/A
- EPS
- TLRY N/A
- KNSA N/A
- Revenue
- TLRY $812,037,000.00
- KNSA $384,098,000.00
- Revenue This Year
- TLRY $18.31
- KNSA $60.05
- Revenue Next Year
- TLRY $5.26
- KNSA $36.32
- P/E Ratio
- TLRY N/A
- KNSA N/A
- Revenue Growth
- TLRY 24.76
- KNSA 54.41
- 52 Week Low
- TLRY $1.33
- KNSA $15.51
- 52 Week High
- TLRY $2.97
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- TLRY 32.83
- KNSA 32.46
- Support Level
- TLRY $1.36
- KNSA $22.62
- Resistance Level
- TLRY $1.51
- KNSA $23.34
- Average True Range (ATR)
- TLRY 0.09
- KNSA 1.18
- MACD
- TLRY -0.03
- KNSA -0.19
- Stochastic Oscillator
- TLRY 4.08
- KNSA 20.27
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.